IDEAS home Printed from https://ideas.repec.org/a/eee/socmed/v178y2017icp167-174.html
   My bibliography  Save this article

Towards a theoretical model on medicines as a health need

Author

Listed:
  • Vargas-Peláez, Claudia Marcela
  • Soares, Luciano
  • Rover, Marina Raijche Mattozo
  • Blatt, Carine Raquel
  • Mantel-Teeuwisse, Aukje
  • Rossi Buenaventura, Francisco Augusto
  • Restrepo, Luis Guillermo
  • Latorre, María Cristina
  • López, José Julián
  • Bürgin, María Teresa
  • Silva, Consuelo
  • Leite, Silvana Nair
  • Mareni Rocha, Farias

Abstract

Medicines are considered one of the main tools of western medicine to resolve health problems. Currently, medicines represent an important share of the countries' healthcare budget. In the Latin America region, access to essential medicines is still a challenge, although countries have established some measures in the last years in order to guarantee equitable access to medicines. A theoretical model is proposed for analysing the social, political, and economic factors that modulate the role of medicines as a health need and their influence on the accessibility and access to medicines. The model was built based on a narrative review about health needs, and followed the conceptual modelling methodology for theory-building. The theoretical model considers elements (stakeholders, policies) that modulate the perception towards medicines as a health need from two perspectives – health and market – at three levels: international, national and local levels. The perception towards medicines as a health need is described according to Bradshaw's categories: felt need, normative need, comparative need and expressed need. When those different categories applied to medicines coincide, the patients get access to the medicines they perceive as a need, but when the categories do not coincide, barriers to access to medicines are created. Our theoretical model, which holds a broader view about the access to medicines, emphasises how power structures, interests, interdependencies, values and principles of the stakeholders could influence the perception towards medicines as a health need and the access to medicines in Latin American countries.

Suggested Citation

  • Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
    • Handle: RePEc:eee:socmed:v:178:y:2017:i:c:p:167-174
    DOI: 10.1016/j.socscimed.2017.02.015
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0277953617301041
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.socscimed.2017.02.015?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Úrsula Giedion & Ignez Tristao & Liliana Escobar & Ricardo Bitrán & Oscar Cañón & Silvia Molins & Lucía Alonso & Jorge Fernández & Giota Panopoulou & Eduardo González-Pier & A. Lorena Prieto & Camilo , 2014. "Health Benefit Plans in Latin America: A Regional Comparison," IDB Publications (Books), Inter-American Development Bank, number 85095 edited by Úrsula Giedion & Ricardo Bitrán & Ignez Tristao, February.
    2. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    3. Abraham, John, 2010. "On the prohibition of conflicts of interest in pharmaceutical regulation: Precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin," Social Science & Medicine, Elsevier, vol. 70(5), pages 648-651, March.
    4. Vargas-Peláez, Claudia Marcela & Rover, Marina Raijche Mattozo & Leite, Silvana Nair & Rossi Buenaventura, Francisco & Farias, Mareni Rocha, 2014. "Right to health, essential medicines, and lawsuits for access to medicines – A scoping study," Social Science & Medicine, Elsevier, vol. 121(C), pages 48-55.
    5. Hopkins, Michael M. & Martin, Paul A. & Nightingale, Paul & Kraft, Alison & Mahdi, Surya, 2007. "The myth of the biotech revolution: An assessment of technological, clinical and organisational change," Research Policy, Elsevier, vol. 36(4), pages 566-589, May.
    6. Jeffers, J.R. & Bognanno, M.F. & Bartlett, J.C., 1971. "On the demand versus need for medical services and the concept of "shortage"," American Journal of Public Health, American Public Health Association, vol. 61(1), pages 46-63.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. G. Kent Fellows & Daniel J. Dutton & Aidan Hollis, 2018. "Making Sure Orphan Drugs Don’t Get Left Behind," SPP Communique, The School of Public Policy, University of Calgary, vol. 10(6), August.
    2. Makai, Peter & Brouwer, Werner B.F. & Koopmanschap, Marc A. & Stolk, Elly A. & Nieboer, Anna P., 2014. "Quality of life instruments for economic evaluations in health and social care for older people: A systematic review," Social Science & Medicine, Elsevier, vol. 102(C), pages 83-93.
    3. Alberto Onetti & Hal Steger, 2007. "Formulating an open source business model requires community segmentation and targeted marketing," Economics and Quantitative Methods qf0707, Department of Economics, University of Insubria.
    4. Alessia Pisoni & Alberto Onetti & Luciano Fratocchi & Marco Talaia, 2010. "Managing R&D activities in the Italian red biotech industry. A comparison between Italian independent firms and multinational companies," Economics and Quantitative Methods qf1003, Department of Economics, University of Insubria.
    5. Tylecote, Andrew, 2019. "Biotechnology as a new techno-economic paradigm that will help drive the world economy and mitigate climate change," Research Policy, Elsevier, vol. 48(4), pages 858-868.
    6. Fabio Sorrentino & Francesco Garraffo, 2012. "Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 449-475, August.
    7. Victoria Menil, 2015. "Missed Opportunities in Global Health: Identifying New Strategies to Improve Mental Health in LMICs," Working Papers id:7987, eSocialSciences.
    8. Kotiranta, Annu – Kulvik & Tahvanainen, Antti – Trieste, . "Raiders Of Lost Value," ETLA B, The Research Institute of the Finnish Economy, number 267, June.
    9. Pereira, Cristiano Gonçalves & Lavoie, Joao Ricardo & Garces, Edwin & Basso, Fernanda & Dabić, Marina & Porto, Geciane Silveira & Daim, Tugrul, 2019. "Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model," Technological Forecasting and Social Change, Elsevier, vol. 139(C), pages 185-199.
    10. Roberta Piergiovanni & Enrico Santarelli, 2013. "The more you spend, the more you get? The effects of R&D and capital expenditures on the patenting activities of biotechnology firms," Scientometrics, Springer;Akadémiai Kiadó, vol. 94(2), pages 497-521, February.
    11. Irina Dezhina & V. Kiseleva, 2008. "State, Science and Business in Russia's Innovation System," Research Paper Series, Gaidar Institute for Economic Policy, issue 115P.
    12. DiVito, Lori, 2012. "Institutional entrepreneurship in constructing alternative paths: A comparison of biotech hybrids," Research Policy, Elsevier, vol. 41(5), pages 884-896.
    13. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    14. Anita Chawla & Ginger Carls & Edmund Deng & Edward Tuttle, 2015. "The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation," PharmacoEconomics, Springer, vol. 33(7), pages 749-763, July.
    15. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
    16. Antonio Messeni Petruzzelli & Daniele Rotolo & Vito Albino, 2014. "Determinants of Patent Citations in Biotechnology: An Analysis of Patent Influence Across the Industrial and Organizational Boundaries," SPRU Working Paper Series 2014-05, SPRU - Science Policy Research Unit, University of Sussex Business School.
    17. Valérie Sabatier & Vincent Mangematin & Tristan Rouselle, 2010. "From Business model to Business model portfolio in the european biopharmaceutical industry," Post-Print hal-00430782, HAL.
    18. Kyu-Taik Sung, 1992. "Indentification and prioritization of needs of families by multiple groups: Residents, key informants, and agency directors," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 26(2), pages 137-158, March.
    19. repec:mpr:mprres:3307 is not listed on IDEAS
    20. van Rijnsoever, Frank J. & Eveleens, Chris P., 2021. "Money Don't matter? How incubation experience affects start-up entrepreneurs' resource valuation," Technovation, Elsevier, vol. 106(C).
    21. Medina-Molotla, Nelly & Thorsteinsdóttir, Halla & Frixione, Eugenio & Kuri-Harcuch, Walid, 2017. "Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center," Technology in Society, Elsevier, vol. 48(C), pages 1-10.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:178:y:2017:i:c:p:167-174. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.